Valneva (NASDAQ:VALN) Shares Gap Up – Still a Buy?

Valneva SE Sponsored ADR (NASDAQ:VALN) gapped up before the market opened on Tuesday. The stock had previously closed at $5.74, but opened at $6.04. Valneva shares last traded at $5.8410, with a volume of 735 shares trading hands.

Analyst Ratings Changes

A number of equities analysts recently commented on VALN shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Valneva in a report on Monday, September 14th. TD Cowen began coverage on shares of Valneva in a report on Tuesday, August 11th. They issued a “buy” rating and a $12.00 target price on the stock. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Reduce” and a consensus target price of $9.30.

Valneva Stock Up 0.4%

The company’s 50-day moving average price is $6.24 and its 200 day moving average price is $5.94. The company has a debt-to-equity ratio of 2.04, a quick ratio of 1.69 and a current ratio of 2.16. The stock has a market cap of $554.63 million, a PE ratio of -2.77 and a beta of 1.53.

Valneva (NASDAQ:VALN) last announced its earnings results on Friday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.21). Valneva had a negative net margin of 110.33% and a negative return on equity of 153.20%. The business had revenue of $39.37 million for the quarter, compared to the consensus estimate of $44.17 million. As a group, analysts forecast that Valneva SE Sponsored ADR will post -1.27 EPS for the current fiscal year.

Valneva Company Profile

Valneva SE is a specialty vaccine company headquartered in Saint-Herblain, France. The company develops, manufactures and commercializes vaccines intended to address infectious diseases with significant unmet medical needs, including travel-related illnesses, endemic diseases and emerging public-health threats.

Valneva’s marketed products include IXIARO, a vaccine for Japanese encephalitis, and DUKORAL, an oral vaccine used for protection against cholera and certain types of traveler’s diarrhea.